Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
6
Next ›
Last »
Prevision Policy Clips | FDA’s Gastrointestinal Drugs Advisory Committee To Review Intercept’s Ocaliva For NASH On May 19
March 10, 2023
HCV Subscription Model Is $11 Bil. Silver Lining For Drug Developers In White House Budget; Price Cuts Are Much Bigger Item, But Far Less Viable
March 10, 2023
Prevision Policy Clips | House Opioid Bill Would Require Manufacturers And Distributors To Report “Suspicious” Orders
March 9, 2023
Cell Therapy “Assessment Aid” Would Encourage Use Of Data Extrapolation For Next-Generation Oncology Indications; CBER Is Open To Idea
March 9, 2023
FDA Questions “Modest” Efficacy Of Genentech Polivy In First-Line DBCL Setting; Accelerated Approval Status For Refractory Disease Not At Issue For Panel Review
March 8, 2023
Prevision Policy Clips | Covis Admits Defeat On Makena, But Still Hoping To Set Timeline For Withdrawal
March 8, 2023
Prevision Policy Clips | $200 Bil. More: Biden Budget Proposal Would Increase Number Of Medicare Negotiation-Eligible Drugs, Speed Up Timelines
March 7, 2023
Return Of The IPI? MedPAC Members Urge More Work On Part B Pricing After Current Set Of Recommendations Is Done; “Excessive Price” Authority Is Theme To Watch
March 6, 2023
Prevision Policy Clips | Leqembi Advisory Committee Review Will Be Another Accelerated Approval Milestone
March 6, 2023
GSK RSV Vaccine Arexvy: Two Strong Votes By FDA Committee Are Tempered By Repeated Suggestions To Wait For Second Year Data
March 3, 2023
Prevision Policy Clips | FDA's Revamped Manufacturing Inspections Platform Will Launch In 2024
March 3, 2023
FDA Artificial Intelligence In Drug Manufacturing Discussion Paper Raises The Issue That Data Management Practices May Affect Inspections
March 2, 2023
PBM Formulary Design Is One Focus Of Broad Request By GOP House Committee To CVS, Express Scripts And Optum; GPO Affiliates Also Draw Questions
March 2, 2023
Prevision Policy Clips | CMS Updates Drug Spending Dashboards With 2021 Data But Cautions Against Direct Read-Through For “Negotiations”
March 2, 2023
Advisory Committee Tracker: AZ/Merck Lynparza Prostate Cancer Review Extended For ODAC; Paxlovid NDA Conversion Heads To Panel
March 1, 2023
Pfizer RSV Vaccine Clears FDA Committee By Narrow Margins: Discomfort On Safety, Limited Case Counts And “Rushed” Process Is Warning For FDA
March 1, 2023
Prevision Policy Clips | AstraZeneca/MSD’s Lynparza Goes To FDA Advisory Committee For First-Line Metastatic Prostate Cancer
March 1, 2023
Prevision Policy Clips | CDER Liver Drug Division Acting Director Is Frank Anania
February 28, 2023
FDA AI/ML Discussion Paper Will Clarify Issues Around Use Of Artificial Intelligence In Drug Development; FDA Device Effort Provides Model
February 27, 2023
FDA Neurology Office Deputy Buracchio Is Acting Head Following Dunn’s Exit; Consistency A Plus – But Another Neurologist Bites The Dust
February 27, 2023
FDA Evidence Generation Taxonomy, Gene-Editing Information Sharing Initiatives Unveiled By Commissioner Califf As Second Year Priorities
February 27, 2023
Prevision Policy Clips | CDER Office Of Compliance Director Jill Furman Will Stay On
February 27, 2023
Pfizer, GSK RSV Vaccine Candidates: Tandem Reviews To Showcase FDA Post-COVID Vaccine Work And Leadership
February 24, 2023
Gene Therapy BLA Review Teams Will Stay Together As Office of Therapeutic Products Launches Feb. 26; Communication Pilot Will Be Early Highlight
February 24, 2023
Prevision Policy Clips | Pfizer Paxlovid EUA-To-NDA Conversion Heads To Advisory Committee March 16
February 24, 2023
1
2
3
4
5
6
Next ›
Last »